Publications Oncomedics

 

 

Publications de référence

 

  • The value of personalized treatment (Rx) planning (PTP): Cost savings (sav) by the Microculture Kinetic (MiCK) chemosensitivity (CS) assay, evidence from a large American self-insured company (ASIC). Latimer RG, Presant CA, Hallquist AE, Perree M, Agapitos D. Journal of Clinical Oncology, ASCO communication 2009.
  • Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Herzog TJ, Krivak TC, Fader AN, Coleman RL. Am J Obstet Gynecol. 2010 Jul;203(1):68.e1-6.
  • The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. Bosserman L1, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, Raptis A, Hallquist A, Perree M, Rajurkar S, Karimi M, Rogers K, Davidson D, Willis C, Penalver M, Homesley H, Burrell M, Garrett A, Rutledge J, Chernick M, Presant CA. Cancer Res. 2012 Aug 15;72(16):3901-5.
  • Precision medicine for cancer with next-generation functional diagnostics. Friedman AA, Letai A, Fisher DE, Flaherty KT. Nat Rev Cancer. 2015 Dec;15(12):747-56.
  • Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancer. Bosserman L1, Rogers K2, Willis C2, Davidson D3, Whitworth P4, Karimi M1, Upadhyaya G1, Rutledge J5, Hallquist A6, Perree M6, Presant CA7. PLoS One. 2015 May 29;10(5):e0122609.
  • Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis. Blom K, Nygren P, Larsson R, Andersson CR. SLAS Technol. 2017 Jun;22(3):306-314. doi: 10.1177/2472630316686297.